このアイテムのアクセス数: 500

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
69_3_79.pdf657.65 kBAdobe PDF見る/開く
タイトル: 術後放射線療法を施行し5年間再発を認めなかった後腹膜脱分化型脂肪肉腫の1例
その他のタイトル: Retroperitoneal Dedifferentiated Liposarcoma with No Recurrence after 5 Years of Postoperative Radiation Therapy --A Case Report--
著者: 細川, 智加  KAKEN_name
川口, 愛  KAKEN_name
木内, 静香  KAKEN_name
鈴木, 昭  KAKEN_name
永倉, 久泰  KAKEN_name
篠原, 信雄  KAKEN_name
土屋, 邦彦  KAKEN_name
著者名の別形: HOSOKAWA, Chika
KAWAGUCHI, Ai
KIUCHI, Shizuka
SUZUKI, Akira
NAGAKURA, Hisayasu
SHINOHARA, Nobuo
TSUCHIYA, Kunihiko
キーワード: Retroperitoneal liposarcoma
Dedifferentiated liposarcoma
Radiation therapy
発行日: 31-Mar-2023
出版者: 泌尿器科紀要刊行会
誌名: 泌尿器科紀要
巻: 69
号: 3
開始ページ: 79
終了ページ: 83
抄録: A 49-year-old woman presented to our hospital with right lower back pain and epigastric pressure. A computed tomographic scan showed a 12×7×20 cm retroperitoneal mass comprising fatty components and contrast areas around the right kidney. Based on the results, a right retroperitoneal liposarcoma was suspected. Thus, right retroperitoneal tumor resection combined with right kidney resection was performed. Instances of tumor adhesion were found in the ascending colon, duodenum, and the iliopsoas muscle, which could be dissected ; therefore, combined resection of the intestinal tract was not performed. The resected tumor was found to be mixed with dedifferentiated and well-differentiated components and was diagnosed as dedifferentiated liposarcoma. Due to the presence of positive margins, the patient received 50 Gy in 25 fractions of radiation therapy to the right side of the retroperitoneum as postoperative adjuvant therapy. During the irradiation period, vomiting and anorexia were observed as adverse events. Five years have passed since the surgery, and no local recurrence or late complications due to radiation have been observed. Although dedifferentiated liposarcoma is a highly malignant histological type with a very high local recurrence rate, no adjuvant therapy has been established. Some reports have suggested that postoperative radiation therapy for retroperitoneal sarcoma is effective in terms of survival and local control. However, there are no reports of prospective clinical trials, and the evidence is expected to widen in the near future.
著作権等: 許諾条件により本文は2024-04-01に公開
DOI: 10.14989/ActaUrolJap_69_3_79
URI: http://hdl.handle.net/2433/281590
PubMed ID: 37038347
出現コレクション:Vol.69 No.3

アイテムの詳細レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。